Telavancin  (Synonyms: TD-6424)

Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria^[1].

Telavancin has a rapid, concentration-dependent bactericidal effect, due to disruption of cell membrane integrity^[1].
Telavancin (5 μg/mL) exerts bacteriocidal effect against a MRSA strain (COL) and a VISA strain (HIP5836) at a concentration of 5 µg/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Telavancin has been tested in various relevant animal models of infection, namely, bacteremia (40 mg/kg/d; s.c.; twice a day, with 12 h space), endocarditis (30 mg/kg/d; i.v.; twice a day, with 12 h space; 4 d), meningitis, and pneumonia with success^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1755.63

C₈₀H₁₀₆Cl₂N₁₁O₂₇P

372151-71-8

Solid

White to off-white

ClC1=CC([C@H]([C@](C(N[C@@H]2C(O)=O)=O)([H])N3)O)=CC=C1OC4=CC([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C3=O)([H])C(C=C6C(C2=CC(O)=C7CNC[P](O)(O)=O)=C7O)=CC=C6O)=O)=CC(OC8=CC=C([C@H]([C@H]5NC([C@H](NC)CC(C)C)=O)O)C=C8Cl)=C4O[C@H](O[C@@H]9CO)[C@@H]([C@H]([C@@H]9O)O)O[C@H](O[C@H]%10C)C[C@@](C)([C@@H]%10O)NCCNCCCCCCCCCC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Das B, et al. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis. 2017 Mar;4(2):49-73.   [Content Brief]